Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKX019 + rituximab
- Development stage
- Unknown
- Lead developer
- Nkarta
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NKX019 + rituximab is an investigational combination therapy composed of **NKX019**, an allogeneic, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy engineered to target CD19 on B-cells, and **rituximab**, a monoclonal antibody targeting CD20 on B-cells. The combination is being evaluated for enhanced anti-tumor activity and antibody-dependent cellular cytotoxicity (ADCC) in B-cell malignancies and is under exploration for autoimmune diseases. NKX019 is derived from healthy donor peripheral blood NK cells, genetically modified with CAR targeting CD19 and containing a membrane-bound IL-15 for improved cell survival and activity. **Rituximab** binds to CD20, inducing B-cell depletion via various immune mechanisms. The combination aims to synergistically eliminate pathogenic B-cells and promote long-term remission or tumor reduction[7][9].
- Other names
- NKX019 + rituximab
02
Targets
Beyond the preview
Go deeper on NKX019 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKX019 + rituximab.